;PMID: 6974914
;source_file_999.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..31] = [t:0..31]
;1)sentence:[e:37..161] = [t:37..161]
;2)section:[e:165..216] = [t:165..216]
;3)sentence:[e:220..385] = [t:220..385]
;4)sentence:[e:386..532] = [t:386..532]
;5)sentence:[e:534..601] = [t:534..601]
;6)sentence:[e:602..956] = [t:602..956]
;7)sentence:[e:957..1179] = [t:957..1179]
;8)sentence:[e:1181..1296] = [t:1181..1296]
;9)section:[e:1300..1344] = [t:1300..1344]

;section 0 Span:0..31
;Steroids. 1981 Jun;37(6):673-9.
(SEC
  (FRAG (NNP:[0..8] Steroids) (IN:[8..9] .) (CD:[10..14] 1981)
        (NNP:[15..22] Jun;37-LRB-) (CD:[22..24] 6-RRB-) (CD:[24..28] :673)
        (::[28..29] -) (CD:[29..31] 9.)))

;sentence 1 Span:37..161
;Effects of cholesterol side chain cleavage inhibitors on 11
;beta-hydroxylation:  linkage of mitochondrial oxygenase systems.
;[48..79]:cyp450:"cholesterol side chain cleavage"
;[80..90]:substance:"inhibitors"
;[143..152]:substance:"oxygenase"
(SENT
  (NP-HLN
    (NP
      (NP (NNS:[37..44] Effects))
      (PP (IN:[45..47] of)
        (NP
           (NN:[48..59] cholesterol)
          (NML
            (NML (NN:[60..64] side) (IN:[65..70] chain))
            (NN:[71..79] cleavage))
          (NNS:[80..90] inhibitors)))
      (PP (IN:[91..93] on)
        (NP (CD:[94..96] 11) (NN:[97..115] beta-hydroxylation))))
    (::[115..116] :)
    (NP
      (NP (NN:[118..125] linkage))
      (PP (IN:[126..128] of)
        (NP (JJ:[129..142] mitochondrial) (NN:[143..152] oxygenase)
            (NNS:[153..160] systems))))
    (.:[160..161] .)))

;section 2 Span:165..216
;Whipple CA, Grodzicki RL, Hourihan J, Salhanick HA.
(SEC
  (FRAG (NNP:[165..172] Whipple) (NNP:[173..175] CA) (,:[175..176] ,)
        (NNP:[177..186] Grodzicki) (NNP:[187..189] RL) (,:[189..190] ,)
        (NNP:[191..199] Hourihan) (NNP:[200..202] J,) (NNP:[203..212] Salhanick)
        (NNP:[213..215] HA) (.:[215..216] .)))

;sentence 3 Span:220..385
;Potent inhibitors of cholesterol side chain cleavage were tested for
;inhibition  of 11 beta-hydroxylation of 11-deoxycortisol by bovine adrenal
;cortex  mitochondria.
;[227..237]:substance:"inhibitors"
;[241..272]:cyp450:"cholesterol side chain cleavage"
;[329..345]:substance:"11-deoxycortisol"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[220..226] Potent) (NNS:[227..237] inhibitors))
      (PP (IN:[238..240] of)
        (NP (NN:[241..252] cholesterol)
          (NML (NN:[253..257] side) (NN:[258..263] chain))
          (NN:[264..272] cleavage))))
    (VP (VBD:[273..277] were)
      (VP (VBN:[278..284] tested)
        (NP-1 (-NONE-:[284..284] *))
        (PP (IN:[285..288] for)
          (NP
            (NP (NN:[289..299] inhibition))
            (PP (IN:[301..303] of)
              (NP
                (NP (CD:[304..306] 11) (NN:[307..325] beta-hydroxylation))
                (PP (IN:[326..328] of)
                  (NP (NN:[329..345] 11-deoxycortisol)))))
            (PP (IN:[346..348] by)
              (NP (JJ:[349..355] bovine)
                (NML (JJ:[356..363] adrenal) (NN:[364..370] cortex))
                (NNS:[372..384] mitochondria)))))))
    (.:[384..385] .)))

;sentence 4 Span:386..532
;Compounds which inhibited 11 beta-hydroxylation were metyrapone, 
;4-phenylimidazole, 1-benzylimidazole, 17 beta-ureido - 1, 4-
;androstadien-3-one.
;[386..395]:substance:"Compounds"
;[439..449]:substance:"metyrapone"
;[452..469]:substance:"4-phenylimidazole"
;[471..488]:substance:"1-benzylimidazole"
;[490..531]:substance:"17 beta-ureido - 1, 4- androstadien-3-one"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[386..395] Compounds))
      (SBAR
        (WHNP-1 (WDT:[396..401] which))
        (S
          (NP-SBJ-1 (-NONE-:[401..401] *T*))
          (VP (VBD:[402..411] inhibited)
            (NP (CD:[412..414] 11) (NN:[415..433] beta-hydroxylation))))))
    (VP (VBD:[434..438] were)
      (NP-PRD
        (NP (NN:[439..449] metyrapone))
        (,:[449..450] ,)
        (NP (NN:[452..469] 4-phenylimidazole))
        (,:[469..470] ,)
        (NP (NN:[471..488] 1-benzylimidazole))
        (,:[488..489] ,)
        (NP (CD:[490..492] 17)
            (NN:[493..531] beta-ureido-SP---SP-1,-SP-4--SP-androstadien-3-one))))
    (.:[531..532] .)))

;sentence 5 Span:534..601
;SU-8000, 4-methylaminoglutethimide, and 20 alpha-hydroxycholestrol.
;[534..541]:substance:"SU-8000"
;[543..568]:substance:"4-methylaminoglutethimide"
;[574..600]:substance:"20 alpha-hydroxycholestrol"
(SENT
  (FRAG
    (NP
      (NP (NN:[534..541] SU-8000))
      (,:[541..542] ,)
      (NP (NN:[543..568] 4-methylaminoglutethimide))
      (,:[568..569] ,) (CC:[570..573] and)
      (NP (CD:[574..576] 20) (NN:[577..600] alpha-hydroxycholestrol)))
    (.:[600..601] .)))

;sentence 6 Span:602..956
;Compounds  which did not inhibit 11 beta-hydroxylation at concentrations of
;0.5 mM were  d-aminoglutethimide tartrate, 1-aminoglutethimide tartrate, 
;N-methylaminoglutethimide, 16 alpha-methylpregnenolone, 16 
;beta-methylpregnenolone, 20-tolylpregnenediol, 16 
;alpha-chloropregnenolone-3-acetate, 16 alpha-benzyloxpregnenolone-3-acetate
;and  cyanoketone.
;[602..611]:substance:"Compounds"
;[678..681]:quantitative-value:"0.5"
;[682..684]:quantitative-units:"mM"
;[691..719]:substance:"d-aminoglutethimide tartrate"
;[721..749]:substance:"1-aminoglutethimide tartrate"
;[752..777]:substance:"N-methylaminoglutethimide"
;[779..806]:substance:"16 alpha-methylpregnenolone"
;[808..835]:substance:"16  beta-methylpregnenolone"
;[837..857]:substance:"20-tolylpregnenediol"
;[859..897]:substance:"16  alpha-chloropregnenolone-3-acetate"
;[899..938]:substance:"16 alpha-benzyloxpregnenolone-3-acetate"
;[944..955]:substance:"cyanoketone"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[602..611] Compounds))
      (SBAR
        (WHNP-1 (WDT:[613..618] which))
        (S
          (NP-SBJ-1 (-NONE-:[618..618] *T*))
          (VP (VBD:[619..622] did) (RB:[623..626] not)
            (VP (VB:[627..634] inhibit)
              (NP (CD:[635..637] 11) (NN:[638..656] beta-hydroxylation))
              (PP (IN:[657..659] at)
                (NP
                  (NP (NNS:[660..674] concentrations))
                  (PP (IN:[675..677] of)
                    (NP (CD:[678..681] 0.5) (NN:[682..684] mM))))))))))
    (VP (VBD:[685..689] were)
      (NP-PRD
        (NP (NN:[691..710] d-aminoglutethimide) (NN:[711..719] tartrate))
        (,:[719..720] ,)
        (NP (NN:[721..740] 1-aminoglutethimide) (NN:[741..749] tartrate))
        (,:[749..750] ,)
        (NP (NN:[752..777] N-methylaminoglutethimide))
        (,:[777..778] ,)
        (NP (CD:[779..781] 16) (NN:[782..806] alpha-methylpregnenolone))
        (,:[806..807] ,)
        (NP (CD:[808..810] 16) (NN:[812..835] beta-methylpregnenolone))
        (,:[835..836] ,)
        (NP (NN:[837..857] 20-tolylpregnenediol))
        (,:[857..858] ,)
        (NP (CD:[859..861] 16)
            (NN:[863..897] alpha-chloropregnenolone-3-acetate))
        (,:[897..898] ,)
        (NP (CD:[899..901] 16)
            (NN:[902..938] alpha-benzyloxpregnenolone-3-acetate))
        (CC:[939..942] and)
        (NP (NN:[944..955] cyanoketone))))
    (.:[955..956] .)))

;sentence 7 Span:957..1179
;The results obtained indicate that aminoglutethimide and its  congeners, the
;16-halogenated and 16-benzoylated derivatives of pregnenolone and 
;cyanoketone are specific inhibitors of cholesterol side chain cleavage
;enzyme.
;[992..1009]:substance:"aminoglutethimide"
;[1019..1028]:substance:"congeners"
;[1034..1048]...[1068..1079]:substance:"16-halogenated"..."derivatives"
;[1053..1079]:substance:"16-benzoylated derivatives"
;[1083..1095]:substance:"pregnenolone"
;[1101..1112]:substance:"cyanoketone"
;[1126..1136]:substance:"inhibitors"
;[1140..1178]:cyp450:"cholesterol side chain cleavage enzyme"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[957..960] The) (NNS:[961..968] results))
      (VP (VBN:[969..977] obtained)
        (NP (-NONE-:[977..977] *))))
    (VP (VBP:[978..986] indicate)
      (SBAR (IN:[987..991] that)
        (S
          (NP-SBJ
            (NP (NN:[992..1009] aminoglutethimide))
            (CC:[1010..1013] and)
            (NP
              (NP (PRP$:[1014..1017] its) (NNS:[1019..1028] congeners))
              (,:[1028..1029] ,)
              (NP
                (NP (DT:[1030..1033] the)
                  (ADJP (VBN:[1034..1048] 16-halogenated) (CC:[1049..1052] and)
                        (VBN:[1053..1067] 16-benzoylated))
                  (NNS:[1068..1079] derivatives))
                (PP (IN:[1080..1082] of)
                  (NP (NN:[1083..1095] pregnenolone) (CC:[1096..1099] and)
                      (NN:[1101..1112] cyanoketone))))))
          (VP (VBP:[1113..1116] are)
            (NP-PRD
              (NP (JJ:[1117..1125] specific) (NNS:[1126..1136] inhibitors))
              (PP (IN:[1137..1139] of)
                (NP (NN:[1140..1151] cholesterol)
                  (NML
                    (NML (NN:[1152..1156] side) (NN:[1157..1162] chain))
                    (NN:[1163..1171] cleavage))
                  (NN:[1172..1178] enzyme))))))))
    (.:[1178..1179] .)))

;sentence 8 Span:1181..1296
;The two mitochondrial steroid oxyganase systems are linked through their 
;competition for a single electron source.
;[1203..1220]:substance:"steroid oxyganase"
(SENT
  (S
    (NP-SBJ-1 (DT:[1181..1184] The) (CD:[1185..1188] two)
      (NML (JJ:[1189..1202] mitochondrial) (NN:[1203..1210] steroid))
      (NN:[1211..1220] oxyganase) (NNS:[1221..1228] systems))
    (VP (VBP:[1229..1232] are)
      (VP (VBN:[1233..1239] linked)
        (NP-1 (-NONE-:[1239..1239] *))
        (PP-MNR (IN:[1240..1247] through)
          (NP
            (NP (PRP$:[1248..1253] their) (NN:[1255..1266] competition))
            (PP (IN:[1267..1270] for)
              (NP (DT:[1271..1272] a) (JJ:[1273..1279] single)
                  (NN:[1280..1288] electron) (NN:[1289..1295] source)))))))
    (.:[1295..1296] .)))

;section 9 Span:1300..1344
;PMID: 6974914 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1300..1304] PMID) (::[1304..1305] :) (CD:[1306..1313] 6974914)
        (NN:[1314..1315] -LSB-) (NNP:[1315..1321] PubMed) (::[1322..1323] -)
        (NN:[1324..1331] indexed) (IN:[1332..1335] for)
        (NNP:[1336..1344] MEDLINE-RSB-)))
